These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2008-002396-28 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor... 2009-04-15 due-trials
Completed, but no date, and reported results Terminated 2009-010435-40 Un estudio de fase 2 multicéntrico para evaluar la eficacia y seguridad del IPI-504 en combinación con trastuzumab en pacientes con cáncer de mama pretratado, localmente avanzado o metastásico, positi... bad-data
Reported results 2010-024518-74 A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients with Metastatic or Locally Advanced (Unresectable) Chondrosarcoma 2013-10-15 due-trials
Reported results 2011-000201-44 A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated patients with Stage IIIB or IV Non-Small Cell Lung Cancer 2014-03-05 due-trials
Reported results 2012-001729-28 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose, Cross-Over, Efficacy and Safety Study of IPI-145 in Mild Asthmatic Subjects Undergoing Allergen Challenge 2014-07-30 due-trials
Reported results 2012-003724-20 A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an In... 2014-12-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-002405-61 A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2020-12-23 bad-data
Reported results 2013-002406-31 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of IPI-145 in Combination with Rituximab vs Rituximab in Subjects with Previously-Treated Follicular Lymphoma 2017-03-03 due-trials
Reported results 2013-003639-31 A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07 2020-06-12 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-004008-20 A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma. 2020-11-05 bad-data
Reported results 2014-005459-13 A Two-arm, Phase 1b/2 Study of IPI-145 Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma 2017-02-13 due-trials
Listed as ongoing, but also has a completion date 2015-004033-28 A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects wi... 2016-06-28 bad-data
Not reported 2015-004729-15 A Phase 2, Randomized Study of Duvelisib Administered in Combination with Rituximab vs R-CHOP in Subjects with Relapsed/Refractory Follicular Lymphoma 2016-10-14 due-trials
Not reported 2019-000854-69 A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination with IPI 549 Compared to Nivolumab Monotherapy in th... 2022-11-10 due-trials